3Abdalla SA, Gallione CJ, Barst P,J, et al. Primary pulmonary hypertension in families with hereditary hemorrhagic telangiectasia[J]. Eur Respir J, 2004,23 ( 3 ):373 - 377.
4Karatza AA, Bush A, Magee AG. Safety and efficacy of Sildenafil therapy in children with pulmonary hypertension[J].Int J Cardiol, 2005,100(2) :267 - 273.
6Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension [J]. Int J Cardiol, 2005,99( 1 ) : 91 - 95.
2NIH Consensus Conference on Impotence. NIH Consensus Development Panel on Impotence[ J]. JAMA, 1993, 270( 1 ):83-90.
3Plaud J, Dubbert PM, Holm J, et al. Erectile dysfunction in men with chronic medical illness[J]. J Beh Ther Exp Psychiat, 1996,27(1) :11-19.
4Slag M, Morley JE, Elson MK, et al. Impotence in medical clinic outpatients[J]. JAMA, 1983, 249(13) :1736-1740.
5Spark RF, White RA, Connolly PB. Impotence is not always psychogenic: Newer insights into hypothalamic-pituitary-gonadal dysfunction[J]. JAMA, 1980, 243(8) :750-755.
6Morley J. Impotence[J]. Am J Med, 1986, 80(5): 897-905.
7Krane RJ,Goldstein I, Tejada IS. Impotence [ J ]. New Eng J Med,1989, 321 (24): 1648-1659.
8National Institute of Diabetics, Digestive, Kidney Disease. National kidney and urologic diseases information clearing house[M]. NIH Publication Co. , 1995. 95-392.
9Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study[ J]. J Urol, 1994, 151 ( 1 ) :54-61.
10Ayta IA, McKinlay JB, Krane RJ. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences[J]. BJU Int, 1999, 84( 1 ): 50-56.
